ARAF and lung carcinoma: ARAF p.S214C-mutated lung cancer cells demonstrate remarkable sorafenib sensitivity in vitro and in vivo, which aligns with a previous clinical report of a lung cancer patient carrying this mutation being an exceptional responder to sorafenib.